US 12,281,120 B2
Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile
Kolbot By, San Ramon, CA (US); Mohammad R. Masjedizadeh, San Jose, CA (US); Pasit Phiasivongsa, Hillsborough, CA (US); and Jiang Zhu, San Ramon, CA (US)
Assigned to Principia Biopharma Inc., Bridgewater, NJ (US)
Filed by Principia Biopharma Inc., Bridgewater, NJ (US)
Filed on Apr. 25, 2023, as Appl. No. 18/306,649.
Application 18/306,649 is a division of application No. 17/143,355, filed on Jan. 7, 2021, granted, now 11,667,641.
Claims priority of provisional application 62/958,389, filed on Jan. 8, 2020.
Prior Publication US 2024/0190882 A1, Jun. 13, 2024
Int. Cl. A61K 31/519 (2006.01); C07D 487/04 (2006.01)
CPC C07D 487/04 (2013.01) [C07B 2200/13 (2013.01)] 8 Claims
 
1. Crystalline Form (II) of Compound (I):

OG Complex Work Unit Chemistry
wherein crystalline Form (II) is characterized by an X-ray powder diffractogram comprising at least one signal at a value (°2θ) chosen from 15.2°±0.2 °2θ, 16.0°±0.2 °2θ, 16.6°±0.2 °2θ, 17.7°±0.2 °2θ, 20.02+0.2 °2θ, 24.8°±0.2 °2θ, and 27.5°±0.2 °2θ.
 
5. A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and the crystalline Form (II) according to claim 1.